Dalvance

Chemical Namedalbavancin
Dosage FormInjection (intravenous; 500mg)
Drug ClassAntibacterials
SystemSkin
CompanyAllergan
Approval Year2014

Indication

  • For acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dalvance (dalbavancin) Prescribing Information2014Durata Therapeutics U.S. Limited, Chicago, IL